-
1
-
-
33846227103
-
Implications of prostate-specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancer
-
Maffezzini M, Bossi A, Collette L. Implications of prostate-specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancer. Eur Urol. 2007;51:605-613.
-
(2007)
Eur Urol
, vol.51
, pp. 605-613
-
-
Maffezzini, M.1
Bossi, A.2
Collette, L.3
-
2
-
-
27244451002
-
Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy
-
Zhou P, Chen M-H, McLeod D, Carroll PR, Moul JW, D'Amico AV. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol. 2005;23:6992-6998.
-
(2005)
J Clin Oncol
, vol.23
, pp. 6992-6998
-
-
Zhou, P.1
Chen, M.-H.2
McLeod, D.3
Carroll, P.R.4
Moul, J.W.5
D'Amico, A.V.6
-
3
-
-
22844434877
-
Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy
-
Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294;433-439.
-
(2005)
JAMA
, vol.294
, pp. 433-439
-
-
Freedland, S.J.1
Humphreys, E.B.2
Mangold, L.A.3
-
4
-
-
34249940817
-
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy
-
Stephenson AJ, Scardino PT, Kattan MW, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007;25:2035-2041.
-
(2007)
J Clin Oncol
, vol.25
, pp. 2035-2041
-
-
Stephenson, A.J.1
Scardino, P.T.2
Kattan, M.W.3
-
5
-
-
11144355828
-
Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy
-
Stephenson AJ, Shariat SF, Zelefsky MJ, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA. 2004;291:1325-1332.
-
(2004)
JAMA
, vol.291
, pp. 1325-1332
-
-
Stephenson, A.J.1
Shariat, S.F.2
Zelefsky, M.J.3
-
6
-
-
33947328259
-
Prostate-specific antigen in clinical practice
-
Loeb S, Catalona WJ. Prostate-specific antigen in clinical practice. Cancer Lett. 2007;249:30-39.
-
(2007)
Cancer Lett
, vol.249
, pp. 30-39
-
-
Loeb, S.1
Catalona, W.J.2
-
7
-
-
3042727071
-
Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy
-
D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 2004;351:125-135.
-
(2004)
N Engl J Med
, vol.351
, pp. 125-135
-
-
D'Amico, A.V.1
Chen, M.H.2
Roehl, K.A.3
Catalona, W.J.4
-
8
-
-
27744555727
-
Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy
-
Sengupta S, Myers RP, Slezak JM, Bergstralh EJ, Zincke H, Blute ML. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol. 2005;174:2191-2196.
-
(2005)
J Urol
, vol.174
, pp. 2191-2196
-
-
Sengupta, S.1
Myers, R.P.2
Slezak, J.M.3
Bergstralh, E.J.4
Zincke, H.5
Blute, M.L.6
-
9
-
-
22844433445
-
Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy
-
D'Amico AV, Renshaw AA, Sussman B, Chen MH. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA. 2005;294:440-447.
-
(2005)
JAMA
, vol.294
, pp. 440-447
-
-
D'Amico, A.V.1
Renshaw, A.A.2
Sussman, B.3
Chen, M.H.4
-
10
-
-
33947541761
-
Pretreatment PSA velocity as a predictor of disease outcome following radical radiation therapy
-
Palma D, Tyldesley S, Blood P, Liu M, Morris J, Pickles T. Pretreatment PSA velocity as a predictor of disease outcome following radical radiation therapy. Int J Radiat Oncol Biol Phys. 2007;67:1425-1429.
-
(2007)
Int J Radiat Oncol Biol Phys
, vol.67
, pp. 1425-1429
-
-
Palma, D.1
Tyldesley, S.2
Blood, P.3
Liu, M.4
Morris, J.5
Pickles, T.6
-
11
-
-
0030843379
-
Pretreatment prostate specific antigen doubling times; use in patients before radical prostatectomy
-
discussion
-
Goluboff ET, Heitjan DF, DeVries GM, Katz AE, Benson MC, Olsson CA. Pretreatment prostate specific antigen doubling times; use in patients before radical prostatectomy. J Urol. 1997;158:1876-1878; discussion 1878-1879.
-
(1878)
J Urol. 1997
, vol.158
, pp. 1876-1878
-
-
Goluboff, E.T.1
Heitjan, D.F.2
DeVries, G.M.3
Katz, A.E.4
Benson, M.C.5
Olsson, C.A.6
-
12
-
-
0030047278
-
Pretreatment prostate-specific antigen doubling times: Clinical utility of this predictor of prostate cancer behavior
-
Hanks GE, Hanlon AL, Lee WR, Slivjak A, Schultheiss TE. Pretreatment prostate-specific antigen doubling times: clinical utility of this predictor of prostate cancer behavior. Int J Radiat Oncol Biol Phys. 1996;34:549-553.
-
(1996)
Int J Radiat Oncol Biol Phys
, vol.34
, pp. 549-553
-
-
Hanks, G.E.1
Hanlon, A.L.2
Lee, W.R.3
Slivjak, A.4
Schultheiss, T.E.5
-
13
-
-
0035433469
-
Controversies in prostate cancer radiotherapy: Consensus development
-
Lukka H, Warde P, Pickles T, Morton G, Brundage M, Souhami L. Controversies in prostate cancer radiotherapy: consensus development. Can J Urol. 2001;8:1314-1322.
-
(2001)
Can J Urol
, vol.8
, pp. 1314-1322
-
-
Lukka, H.1
Warde, P.2
Pickles, T.3
Morton, G.4
Brundage, M.5
Souhami, L.6
-
14
-
-
33745184874
-
-
Roach M 3rd, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965-974.
-
Roach M 3rd, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965-974.
-
-
-
-
15
-
-
21144484803
-
On the use of cause-specific failure and conditional failure probabilities: Examples from clinical oncology data
-
Gaynor JJ, Feuer EJ, Tan CC, et al. On the use of cause-specific failure and conditional failure probabilities: examples from clinical oncology data. J Am Stat Assoc. 1993;88:400-409.
-
(1993)
J Am Stat Assoc
, vol.88
, pp. 400-409
-
-
Gaynor, J.J.1
Feuer, E.J.2
Tan, C.C.3
-
16
-
-
1542532754
-
A proportional hazards model for the subdistribution of a competing risk
-
Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496-509.
-
(1999)
J Am Stat Assoc
, vol.94
, pp. 496-509
-
-
Fine, J.P.1
Gray, R.J.2
-
17
-
-
33748672673
-
Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen level
-
D'Amico AV, Loffredo M, Renshaw AA, Loffredo B, Chen MH. Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen level. J Clin Oncol. 2006;24:4190-4195.
-
(2006)
J Clin Oncol
, vol.24
, pp. 4190-4195
-
-
D'Amico, A.V.1
Loffredo, M.2
Renshaw, A.A.3
Loffredo, B.4
Chen, M.H.5
-
18
-
-
34250795026
-
Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors
-
D'Amico AV, Chen MH, Catalona WJ, Sun L, Roehl KA, Moul JW. Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors. Cancer. 2007;110:56-61.
-
(2007)
Cancer
, vol.110
, pp. 56-61
-
-
D'Amico, A.V.1
Chen, M.H.2
Catalona, W.J.3
Sun, L.4
Roehl, K.A.5
Moul, J.W.6
-
19
-
-
42449109218
-
The prostate specific antigen velocity is unaltered by radiotherapy alone when 2 ng/mL per year or greater: Distant metastasis are the cause
-
Presented at the, Philadelphia, Pennsylvania, November 5-9, Abstract 1132
-
Buyyounouski MK, Hanlon AL, Horwitz EM, Pollack A. The prostate specific antigen velocity is unaltered by radiotherapy alone when 2 ng/mL per year or greater: distant metastasis are the cause. Presented at the 48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, Philadelphia, Pennsylvania, November 5-9, 2006. Abstract 1132.
-
(2006)
48th Annual Meeting of the American Society for Therapeutic Radiology and Oncology
-
-
Buyyounouski, M.K.1
Hanlon, A.L.2
Horwitz, E.M.3
Pollack, A.4
|